Single‐Dose Pharmacokinetics and Pharmacodynamics of RWJ 67657, a Specific p38 Mitogen‐Activated Protein Kinase Inhibitor: A First‐in‐Human Study
The DOI matches its Crossref record.
Abstract
The objective of this study was to investigate the pharmacokinetics and ex vivo pharmacodynamics of increasing doses of RWJ 67657, along with the effect of food at one dose level in a first‐in‐human (FIH) study. This was a placebo‐controlled, double‐blind, randomized trial in healthy male subjects. Subjects received increasing doses of RWJ 67657 or placebo as a single oral dose (0.25–30 mg/kg) under fasting conditions. The effect of food was investigated for the 10‐mg/kg dose. Plasma concentrations of RWJ 67657 were measured over a period of 48 hours using a validated LC‐MS/MS method. To evaluate the pharmacodynamics of RWJ 67657, inhibition of cytokine production was monitored from ex vivo—stimulated polymorphonuclear blood cells (PBMCs). Pharmacokinetic/pharmacodynamic modeling was used to characterize the inhibitory activity of RWJ 67657. RWJ 67657 was rapidly absorbed (mean tmax = 0.6–2.5 h). The pharmacokinetics of RWJ 67657 appear to be nonlinear with respect to single‐dose administration of the investigative formulation. Coadministration of food did not have a significant effect on half‐life or time to peak concentration (tmax) but decreased the exposure. Mean Cmax values in the presence of food were almost 50% lower than during fasting (542 vs. 1283 ng/mL), and the AUC decreased from 2832 to 1904 ng•h/mL with food. RWJ 67657 inhibited TNF‐a, IL‐8, and IL‐6 in a concentration‐dependent manner with mean IC50 values of 0.18 μM, 0.04 μM, and 0.43 μM, respectively. At 20 mg/kg, the median inhibition was greater than 85%. There were no significant adverse effects associated with single doses of this drug. This study demonstrates that RWJ 67657 has acceptable safety and pharmacokinetics to warrant further investigation in a repeat‐dose setting. In addition, the early determination of effect on biomarkers suggests potential efficacy in diseases mediated by proinflammatory and inflammatory cytokines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
MAPKs and their relevance to arthritis and inflammation
Thalhamer, T., McGrath, M. A., & Harnett, M. M. (2007) · Rheumatology · doi:10.1093/rheumatology/kem297 · Cited by 460
The many paths to p38 mitogen-activated protein kinase activation in the immune system
Ashwell, J. D. (2006) · Nature Reviews Immunology · doi:10.1038/nri1865 · Cited by 370
Bhattacharyya, S., Brown, D. E., Brewer, J. A., Vogt, S. K., & Muglia, L. J. (2007) · Blood · doi:10.1182/blood-2006-10-048215 · Cited by 249
Mitogen-Activated Protein Kinases as Therapeutic Targets for Rheumatoid Arthritis
Paunovic, V., & Harnett, M. M. (2013) · Drugs · doi:10.1007/s40265-013-0014-6 · Cited by 61
Qin, T., & Gao, S. (2018) · Journal of Ophthalmology · doi:10.1155/2018/5392432 · Cited by 13
Metadata
- Authors
- Parasrampuria, D. A., de Boer, P., Desai‐Krieger, D., Chow, A. T., & Jones, C. R.
- Venue
- The Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2003-04
- Volume
- 43
- Issue
- 4
- Pages
- 406-413
- ISSN
- 0021-9754 (ISSN-L)
- 0091-2700
- 1552-4604
- OpenAlex
- W1997101420
- Cited by
- 52
- References
- 0
- FWCI
- 5.59
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Single‐Dose Pharmacokinetics and Pharmacodynamics of RWJ 67657, a Specific p38 Mitogen‐Activated Protein Kinase Inhibitor: A First‐in‐Human Study. https://app.cochat.ai/papers/10.1177/0091270002250615
- The paper
- Parasrampuria, D. A., de Boer, P., Desai‐Krieger, D., Chow, A. T., & Jones, C. R. (2003). Single‐Dose Pharmacokinetics and Pharmacodynamics of RWJ 67657, a Specific p38 Mitogen‐Activated Protein Kinase Inhibitor: A First‐in‐Human Study. The Journal of Clinical Pharmacology. https://doi.org/10.1177/0091270002250615
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.